Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab With or Without Bevacizumab in Alveolar Soft Part Sarcoma
NCT03141684Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in alveolar soft part sarcoma (ASPS) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Apr 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT03141684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141684.